AndreaBozzo/ceres-open-data-index huggingface dataset:
Ampicillin sodium and sulbactam sodium

Ampicillin and Sulbactam is a prescription antibiotic injection used to treat bacterial infections. It combines ampicillin, a penicillin-type drug, with sulbactam, which helps prevent bacteria from resisting the antibiotic. Administered intravenously by healthcare professionals, it's available as a powder that must be mixed into a solution. This information was generated using AI and is provided for informational and research purposes only.
FY 2012 Children's Bureau Discretionary Grant Awards

This document provides a list of Children's Bureau discretionary grants awarded in fiscal year 2012:

Comprehensive Support Services for Families Affected by Substance Abuse and/or HIV/AIDS HHS-2012-ACF-ACYF-CB-0286

Up to $475,000 per year for up to four years

Family Connection Grants: Child Welfare/TANF Collaboration in Kinship Navigation Programs HHS-2012-ACF-ACYF-CF-0510

Up to $750,000 per year for up to three years

Family Connection Grants: Comprehensive Residential Family Treatment Projects HHS-2012-ACF-ACYF-CF-0511

Up to $600,000 per year for up to three years

Family Connection Grants: Combination Family Finding/Family Group Decision Making HHS-2012-ACF-ACYF-CF-0271

Up to $500,000 per year for up to three years

Child Welfare-Education System Collaboration to Increase Educational Stability HHS-2012-ACF-ACYF-CO-0270

Up to $250,000 per year for up to two years

Child Welfare-Early Education Partnerships to Expand Protective Factors for Children with Early Child Welfare Involvement HHS-2012-ACF-CO-0315

Up to $250,000 per year for up to two years

AdoptUSKids HHS-2012-ACF-ACYF-CQ-0269

Up to $3,669,500 per year for up to five years

Tribal IV-E Plan Development Grants HHS-2012-ACF-ACYF-CS-0280

Up to $300,000 for one 24-month project/budget period

Tribal Court Improvement HHS-2012-ACF-ACYF-CS-0323

Up to $150,000 per year for up to three years

Regional Partnership Grants to Increase the Well-Being of and to Improve the Permanency Outcomes for Children Affected by Substance Abuse HHS-2012-ACF-ACYF-CU-0321

Up to $1,000,000 per year for up to five years

Two Year Extension - Regional Partnership Grants to Increase the Well-Being of and to Improve the Permanency Outcomes for Children Affected by Substance Abuse HHS-2012-ACF-ACYF-CU-0550

$500,000 per year for up to two years

Partnerships to Demonstrate the Effectiveness of Supportive Housing for Families in the Child Welfare System HHS-2012-ACF-ACYF-CA-0538

Up to $1,000,000 per year for up to five years

Initiative to Improve Access to Needs-Driven, Evidence-Based/Evidence-informed Mental and Behavioral Health Services in Child Welfare HHS-2012-ACF-ACYF-CO-0279

Up to $640,000 per year for up to five years

Metadata-only record linking to the original dataset. Open original dataset below.
Healthy People 2020 Overview of Health Disparities

The Overview of Health Disparities analysis is a component of the Healthy People 2020 (HP2020) Final Review. The analysis included 611 objectives in HP2020. This file contains summary level information used for the evaluation of changes in disparities during HP2020, including calculations for the disparities measures and the disparities change categories for all objectives and population characteristics in the analysis. See Technical Notes for the Healthy People 2020 Overview of Health Disparities (https://www.cdc.gov/nchs/healthy_people/hp2020/health-disparities-technical-notes.htm) for additional information and criteria for objectives, data years, and population characteristics included in the analysis and statistical formulas and definitions for the disparities measures. 

Data for additional years during the HP2020 tracking period that are not included in the Overview of Health Disparities are available on the HP2020 website (https://www.healthypeople.gov/2020/). 

Note that “rate” as used may refer to a statistical rate expressed per unit population or a proportion, depending on how the HP2020 objective was defined.
Quality PUF - PY2021

Note: This Public Use File (PUF) was developed using data as of September 29, 2020. Withdrawn, non-certified, stand-alone dental (SADP), indemnity, child-only, suppressed, off-exchange QHPs, and plan IDs with missing or invalid product types are excluded from this data file. Reporting units (the unique combination of issuer ID, state, and plan type) discontinued before June 15, 2019 were exempt from QRS scoring. Reporting units discontinued on the Federally Facilitated Exchange after June 15, 2019 were removed from this PUF.
The 26thCongress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine, Tromso, Norway, 13-17 June 2001

The Congress took place at the northernmost academic center in the world, in the state-of-the art Tromso University Hospital. There were over 500 participants, mainly from Scandinavian countries, with approximately 50 invited participants from non-Scandinavian countries, primarily from Europe and the USA. The meeting was managed and organized by a local committee, chaired by the University of Tromso Professor of Anaesthesiology Dr Lars Bjertneas. Approximately 300 oral and poster presentations highlighted the latest progress in diverse areas of anaesthesiol-ogy and intensive care medicine from Scandinavia. Invited speakers held state-of-the art lectures in selected areas of pathophysiology and therapy. The meeting benefited from the support of various industry sponsors, and the abstracts of the meeting were published in a supplement ofActa Anesthesiologica Scandinavica.
QHP Landscape Instructions PY2025 Dental SHOP

The Dental SHOP Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to employers in the Small Business Health Options Program (SHOP) market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.
Patent AT-E400055-T1: [Translated] SUBSTRATE OF AN OPTICAL DISC AND OPTICAL DISC

Chemical patent from PubChem database. Patent Number: AT-E400055-T1. Title: Novel Drug Delivery System. Filing Date: 1999-12-10. Inventors: Anderson, Robert, Davis, Linda. Abstract: The present invention discloses a drug delivery system designed to provide targeted and sustained release of therapeutic agents, improving patient com... IPC Classifications: C07D, A61K, A61P. This patent covers 47 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians

Background
          A close association between Sst I polymorphism in the 3' untranslated region of the apolipoproteinC3 (APOC3) gene and levels of plasma triglycerides (TG) had been reported by different investigators. Hypertriglyceridemia(HTG) is a known risk factor for coronary artery disease (CAD) in the context of Asian Indians. We conducted a study on the relationship between APOC3 SstI polymorphism (S1S1, S1S2 and S2S2 genotypes) and plasma TG levels in a group of 139 male healthy volunteers from Northern India.
        
        
          Methods
          DNA samples were analyzed by polymerase chain reaction (PCR) followed by SstI digestion. Digested PCR products were run on 3% agarose gel and visualized by ethidium bromide staining.
        
        
          Results
          Rare S2 allele was highly prevalent in our study population (0.313) as compared to the Caucasians (0.00–0.11). The genotypic distribution was in agreement with Hardy-Weinberg equilibrium. S2 allele was almost two times more prevalent in the HTG group (N = 34) as compared to NTG group (N = 105) (p = 0.001). Multiple logistic regression revealed S1S2 individuals had age-adjusted odds ratio of 2.43 (95%CI = 0.99–6.01, p = 0.054) and S2S2 had 9.9 (95%CI = 2.66–37.29, p = 0.0006) for developing HTG in comparison to S1S1 genotype.
        
        
          Conclusions
          Our study shows a significant association between rare S2 allele and HTG in Asian Indians.
Patent AT-E399796-T1: [Translated] METHOD FOR STABILIZING CHIMERIC IMMUNOGLOBULINS OR IMMUNOGLOBULIN FRAGMENTS AND STABILIZED ANTI-EGP-2 SCFV FRAGMENT

The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
Compound 530079: Nonadecane, 8-butyl-9-methyl

Chemical compound data from PubChem database. IUPAC Name: 8-butyl-9-methylnonadecane. Molecular Formula: C24H50. Molecular Weight: 338.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526859: 2-(2-(2-(2-Isopentoxy-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethyl acetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-(3-methylbutoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethyl acetate. Molecular Formula: C17H34O7. Molecular Weight: 350.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Optimisation of transgene action at the post-transcriptional level: high quality parthenocarpic fruits in industrial tomatoes

Background
          Genetic engineering of parthenocarpy confers to horticultural plants the ability to produce fruits under environmental conditions that curtail fruit productivity and quality. The DefH9-iaaM transgene, whose predicted action is to confer auxin synthesis specifically in the placenta, ovules and derived tissues, has been shown to confer parthenocarpy to several plant species (tobacco, eggplant, tomato) and varieties.
        
        
          Results
          UC82 tomato plants, a typical cultivar used by the processing industry, transgenic for the DefH9-iaaM gene produce parthenocarpic fruits that are malformed. UC82 plants transgenic for the DefH9-RI-iaaM, a DefH9-iaaM derivative gene modified in its 5'ULR by replacing 53 nucleotides immediately upstream of the AUG initiation codon with an 87 nucleotides-long sequence derived from the rolA intron sequence, produce parthenocarpic fruits of high quality. In an in vitro translation system, the iaaM mRNA, modified in its 5'ULR is translated 3–4 times less efficiently than the original transcript. An optimal expressivity of parthenocarpy correlates with a reduced transgene mRNA steady state level in DefH9-RI-iaaM flower buds in comparison to DefH9-iaaM flower buds. Consistent with the known function of the iaaM gene, flower buds transgenic for the DefH9-RI-iaaM gene contain ten times more IAA than control untransformed flower buds, but five times less than DefH9-iaaM flower buds.
        
        
          Conclusions
          By using an auxin biosynthesis transgene downregulated at the post-transcriptional level, an optimal expressivity of parthenocarpy has been achieved in a genetic background not suitable for the original transgene. Thus, the method allows the generation of a wider range of expressivity of the desired trait in transgenic plants.
Compound 530433: Methyl 8-methyl-3-(3-phenylprop-2-enoyloxy)-8-azabicyclo[3.2.1]octane-2-carboxylate

Chemical compound data from PubChem database. IUPAC Name: methyl 8-methyl-3-(3-phenylprop-2-enoyloxy)-8-azabicyclo[3.2.1]octane-2-carboxylate. Molecular Formula: C19H23NO4. Molecular Weight: 329.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
GPR99, a new G protein-coupled receptor with homology to a new subgroup of nucleotide receptors

Background
          Based on sequence similarity, the superfamily of G protein-coupled receptors (GPRs) can be subdivided into several subfamilies, the members of which often share similar ligands. The sequence data provided by the human genome project allows us to identify new GPRs by in silico homology screening, and to predict their ligands.
        
        
          Results
          By searching the human genomic database with known nucleotide receptors we discovered the gene for GPR99, a new orphan GPR. The mRNA of GPR99 was found in kidney and placenta. Phylogenetic analysis groups GPR99 into the P2Y subfamily of GPRs. Based on the phylogenetic tree we propose a new classification of P2Y nucleotide receptors into two subgroups predicting a nucleotide ligand for GPR99. By assaying known nucleotide ligands on heterologously expressed GPR99, we could not identify specifically activating substances, indicating that either they are not agonists of GPR99 or that GPR99 was not expressed at the cell surface. Analysis of the chromosomal localization of all genes of the P2Y subfamily revealed that all members of subgroup "a" are encoded by less than 370 kb on chromosome 3q24, and that the genes of subgroup "b" are clustered on one hand to chromosome 11q13.5 and on the other on chromosome 3q24-25.1 close to the subgroup "a" position. Therefore, the P2Y subfamily is a striking example for local gene amplification.
        
        
          Conclusions
          We identified a new orphan receptor, GPR99, with homology to the family of G protein-coupled nucleotide receptors. Phylogenetic analysis separates this family into different subgroups predicting a nucleotide ligand for GPR99.
Compound 530254: Pentadecane, 7-ethyl-6-pentyl

Chemical compound data from PubChem database. IUPAC Name: 7-ethyl-6-pentylpentadecane. Molecular Formula: C22H46. Molecular Weight: 310.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Binding specificity of

Background
          To better understand the molecular interactions of Bt toxins with non-target insects, we have examined the real-time binding specificity and affinity of Cry1 toxins to native silkworm (Bombyx mori) midgut receptors. Previous studies on B. mori receptors utilized brush border membrane vesicles or purifed receptors in blot-type assays.
        
        
          Results
          The Bombyx mori (silkworm) aminopeptidase N (APN) and cadherin-like receptors for Bacillus thuringiensis insecticidal Cry1Aa toxin were purified and their real-time binding affinities for Cry toxins were examined by surface plasmon resonance. Cry1Ab and Cry1Ac toxins did not bind to the immobilized native receptors, correlating with their low toxicities. Cry1Aa displayed moderate affinity for B. mori APN (75 nM), and unusually tight binding to the cadherin-like receptor (2.6 nM), which results from slow dissociation rates. The binding of a hybrid toxin (Aa/Aa/Ac) was identical to Cry1Aa.
        
        
          Conclusions
          These results indicate domain II of Cry1Aa is essential for binding to native B. mori receptors and for toxicity. Moreover, the high-affinity binding of Cry1Aa to native cadherin-like receptor emphasizes the importance of this receptor class for Bt toxin research.
Animal Contact Exhibits_Legal Epidemiology Research Procedure and Code Book_2016

Animals at petting zoos and agricultural fairs can be carriers of pathogens, such as Escherichia coli. Disease outbreaks at animal contact exhibits can be prevented by handwashing after contact with animals and keeping food and beverage away from exhibits. This research procedure and code book accompanies the data set, Animal Contact Exhibits_Legal Epidemiology Dataset_2016, which catalogs and analyzes a collection of state hand sanitation laws for the following categories of animal contact exhibits:
a. Petting zoos
b. Agricultural fairs
c. County or state fairs
d. Exotic animal exhibits
e. Circuses
f. Zoos
Erythropoietin, uncertainty principle and cancer related anaemia

Background
          This study was designed to evaluate if erythropoietin (EPO) is effective in the treatment of cancer related anemia, and if its effect remains unchanged when data are analyzed according to various clinical and methodological characteristics of the studies. We also wanted to demonstrate that cumulative meta-analysis (CMA) can be used to resolve uncertainty regarding clinical questions.
        
        
          Methods
          Systematic Review (SR) of the published literature on the role of EPO in cancer-related anemia. A cumulative meta-analysis (CMA) using a conservative approach was performed to determine the point in time when uncertainty about the effect of EPO on transfusion-related outcomes could be considered resolved. Participants: Patients included in randomized studies that compared EPO versus no therapy or placebo. Main outcome measures: Number of patients requiring transfusions.
        
        
          Results
          Nineteen trials were included. The pooled results indicated a significant effect of EPO in reducing the number of patients requiring transfusions [odds ratio (OR) = 0.41; 95%CI: 0.33 to 0.5; p < 0.00001;relative risk (RR) = 0.61; 95% CI: 0.54 to 0.68]. The results remain unchanged after the sensitivity analyses were performed according to the various clinical and methodological characteristics of the studies. The heterogeneity was less pronounced when OR was used instead of RR as the measure of the summary point estimate. Analysis according to OR was not heterogeneous, but the pooled RR was highly heterogeneous. A stepwise metaregression analysis did point to the possibility that treatment effect could have been exaggerated by inadequacy in allocation concealment and that larger treatment effects are seen at hb level > 11.5 g/dl. We identified 1995 as the point in time when a statistically significant effect of EPO was demonstrated and after which we considered that uncertainty about EPO efficacy was resolved.
        
        
          Conclusion
          EPO is effective in the treatment of anemia in cancer patients. This could have already been known in 1995 if a CMA had been performed at that time.
Where is biological therapy going?

The substantial progress in our understanding of molecular and cellular biology has allowed us to design biological therapeutics ('biologicals') with defined targets and effector functions. These biologicals have greatly contributed to our current knowledge of pathogenetic mechanisms in autoimmune diseases. However, although some of the biologicals have been extremely successful in treating the symptoms of chronic inflammation, biological therapy has not yet met the expectations of permanently silencing the chonic immune response. In this commentary we discuss current concepts and future directions of biological therapy, and the potential usefulness of biologicals as a treatment of human autoimmune diseases in appropriate critical applications with the use of suitably designed agents.
Compound 525563: Tetradecyl heptafluorobutanoate

Chemical compound data from PubChem database. IUPAC Name: tetradecyl 2,2,3,3,4,4,4-heptafluorobutanoate. Molecular Formula: C18H29F7O2. Molecular Weight: 410.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Multisystem Inflammatory Syndrome in Children (MIS-C) National Surveillance - (February 2020 - December 2022)

"This public use dataset includes case-level data from confirmed MIS-C cases with illness onset February 2020 through December 2022 that were reported to CDC’s National MIS-C Surveillance system. Reports are from 55 U.S. jurisdictions (all 50 states plus New York City, Guam, Puerto Rico, US Virgin Islands, and Washington DC). All cases meet the 2020 CDC MIS-C case definition. U.S. jurisdictions voluntarily report potential MIS-C cases to CDC using a standardized case report form. 

To protect patient privacy, location information has been consolidated to census region, illness onset dates have been abbreviated to month-year, and age ranges are provided. The dataset was further deidentified by implementing a k-anonymity threshold of k=3, and suppressing data for Census Region using primary and complementary suppression to protect patient privacy. The following data are included: patient demographics, timing of illness onset, outcomes, organ system involvement, SARS CoV-2 testing, comorbidities, treatment, and COVID-19 vaccination information. “Case definition” organ system involvement is defined according to 2020 CDC MIS-C case definition criteria. “Severe organ involvement” is a subset of case definition organ involvement composed of more severe MIS-C organ manifestations. This definition has been used in several prior publications and is written out in supplemental materials."
Adult Mental Health Tables (Standard Errors and P Values) - 1.1 to 1.68

These are the detailed tables pertaining to adult mental health from the 2010 National Survey on Drug Use and Health (NSDUH). These detailed tables present standard errors for totals and prevalence estimates of past year any mental illness (AMI), serious mental illness (SMI), suicidal thoughts and behavior, major depressive episode (MDE), treatment for depression (among adults with MDE), mental health service utilization, and measuers related to the co-occurrence of mental disorders with substance use or with substance use disorders. Results are provided for age group, gender, race/ethnicity, education level, employment status, poverty level, geographic area, insurance status. Comparisons are made between 2011 and 2002 to 2010.
Compound 528966: 2-Nitro-4-(propan-2-yl)phenol

Chemical compound data from PubChem database. IUPAC Name: 2-nitro-4-propan-2-ylphenol. Molecular Formula: C9H11NO3. Molecular Weight: 181.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.